Interview with Jan Egberts, CEO, OctoPlus N.V.
Clearly the end of 2010 was an exciting time for you. As you entered the transition period as the new CEO of OctoPlus, you also participated in the equity raising.…
Address: Zernikedreef 12, 2333 CL Leiden,Netherlands
Tel: +31 (0)71 524 40 44
OctoPlus is a specialty pharmaceutical company and internationally established as a provider of pharmaceutical development services, drug delivery technology and cGMP manufacturing to biotech and pharma companies worldwide. We develop high-end formulation solutions for our clients in order to help them bring innovative pharmaceutical products from lab bench to the clinic and onto the market. We are one of the leading specialised contract pharmaceutical development companies in the world. We have extensive formulation expertise on all types of active ingredients (small molecules, proteins, peptides, RNA, DNA) and specialise in injectables. We also offer proprietary drug delivery technologies for the development of improved pharmaceutical products with less side effects, increased patient compliance and better efficacy. We do this for our clients based on either marketed or new pharmaceutical ingredients.
OctoPlus is a specialty pharmaceutical company and internationally established as a provider of pharmaceutical development services, drug delivery technology and cGMP manufacturing to biotech and pharma companies worldwide.
Clearly the end of 2010 was an exciting time for you. As you entered the transition period as the new CEO of OctoPlus, you also participated in the equity raising.…
After a successful IPO on Nasdaq in May 2015, Galapagos is ready to continue developing its robust portfolio of clinical-stage breakthrough therapies with the potential to revolutionize existing treatment paradigms.…
The future of drug development is about interacting, sharing and collaborating. The President and CEO of Genmab, an international biotechnology company focusing on differentiated antibody therapeutics for the treatment of…
Despite its diminutive size, the Netherlands has historically carried a large weight in the world because of certain cultural endowments: small but united, entrepreneurial, innovative, and externally oriented. During the…
Given the peculiarities of the pharmaceutical industry in the Netherlands, such as the highest generics penetration rate in Europe, a relatively small manufacturing presence and a considerably regulated market, what…
2010 was a very important year for Ferring as it marks the 60th anniversary of the company’s founding. Amongst the various commemorations this year and in hearing the collective experiences…
The Dutch affiliate of Chiesi was established in 2007 when many changes were occurring in the local industry. The new healthcare system policy went into effect and the market was…
“Two traditions one vision” was the phrase used to describe the 2005 merger that formed Daiichi Sankyo as it is today. While referring specifically to a corporate merger, its message…
Coincidentally, our meeting today comes two days after World Diabetes Day. How was this day commemorated in the Netherlands and how does it attest to the acceptance and awareness of…
Within our reports we typically like to highlight the personalities of the industry and the stories behind the executives that we meet. As you are still relatively new to Ipsen,…
In order to understand the culture behind the business that this association represents, what would you say is the perception of OTC and non-prescriptive drugs in the Netherlands? OTC medicines…
How do you operate in terms of the stakeholder management, with all of your associate members? Do you tend to operate from the committee perspective, or is there an annual…
Having one of the highest penetration rates in Europe, generic medicines play a very important role in the Dutch pharmaceutical market. As this is the principal association for the generics…
See our Cookie Privacy Policy Here
